NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT
Oslo, 25 May 2018: Reference is made to the stock exchange announcements dated 9 May 2018 and 14 May 2018 regarding the subsequent repair issue of up to 4,464,286 new shares (the "Offer Shares") in Vistin Pharma ASA ("Vistin Pharma" or the "Company") at a subscription price of NOK 11.20 per share (the "Subsequent Repair Issue").
The subscription period for the Subsequent Repair Issue will expire today, 25 May 2018, at 16:30 CEST. Correctly completed subscription forms must be received by the subscription office, or, in the case of online subscriptions, be registered, within this deadline. Subscription rights that are not used to subscribe for Offer Shares within this deadline will have no value and lapse without compensation to the holder.
For more information, please refer to the prospectus of the Company dated 9 May 2018. The Prospectus including the subscription form is available at the following websites: http://www.vistin.com/ and www.dnb.no/emisjoner.
DNB Markets, a part of DNB Bank ASA, is acting as Manager for the Subsequent Repair Issue.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Gunnar Manum
CFO
+47 951 79 190